Epigenetic risk management

Given the challenge of finding safe molecules against epigenetic targets outside of cancer, Atlas Venture and Johnson & Johnson Development Corp. are taking a stepwise approach to financing Rodin Therapeutics Inc. In the past year the neurology company has done enough preclinical work to convince investors to put down the next chunk of cash via last week's $12.9 million series A round.